ENDUR-ACIN® is an effective treatment for hyperlipidemia in patients with ischemic heart disease, especially if fibrates are contraindicated

Summary

This comparison study explores the relative efficacy of long-term use of ENDUR-ACIN® or a fibrate drug in combination with a heart healthy diet for treatment of hyperlipidemia in patients with ischemic heart disease.

For this study, researchers enrolled 93 patients, aged 50-65 years. The use of ENDUR-ACIN® (1,500 mg/day) for 16-24 weeks reduced cholesterol by 16%, low density lipoproteins by 19%, and triglycerides by 26%, and increased high density lipoproteins by 16%. The fibrate drug Besafibrat (Germany), given at a dose indicated for isolated hypertriglyceridemia (600 mg/day) reduced triglycerides by 41%. Diet alone had no significant effect on lipid profiles.

These findings indicate ENDUR-ACIN® is an effective treatment for hyperlipidemia in patients with ischemic heart disease, especially if fibrates are contraindicated.